0,1,2,3,4,5,6
Table 6.3.6:  Randomized trials investigating dose escalation for SRT without ADT and without PET-CT,,,,,,
Trial,n,PCa   condition,Radiotherapy   Dose,Follow-up   (median),Outcome,Results
"SAKK 09/10   trial, 2021   [924]",350,pT2a-3b  R0 – R1  pN0 or cN0  PSA post-op  undetectable  (< 0.1 ng/mL)  or persistent  (> 0.1 ng/mL    < 0.4 ng/mL),64 Gy vs.70 Gy  No ADT allowed  VMAT + IGRT:   57%  3-D planning:   43%,6.2 yr.,Primary   endpoint:  FFBP,6 yr. FFBP:  62% vs. 61%  OS: no difference  Late side effects:  GI grade 2:   7.3% vs. 20%  GI grade 3:  4.2% vs. 2.3%  p for > grade 2/3:  0.009
"Phase-III-Trial   Qi X, et al.,   2020 [1057]",144  ART: 33%  SRT: 67%,pT2-4  R0-R1  pN0 or cN0  Med. PSA    pre-RT:    0.2 ng/mL,"66 Gy vs.  72 Gy  All patients   VMAT + IGRT  No ADT allowed  High risk  (pT3–4, GS: 8–10,  PSA > 20 ng/mL):  whole pelvis RT:   126 (87.5%)",49 mo.,Primary   endpoint:  FFBP,4 yr. FFBP:  75.9% vs. 82.6%  (p > 0.05)  High risk (GS: 8–10):  55.7% vs. 79.7%  p < 0.049)  Late side effects:  GI + GU grade 2  p > 0.05  No grade 3
